ASND vs NVO: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVO is the larger of the two ($178.19B market cap): the incumbent the market prices for continued execution (11.94x forward earnings, beta 0.37). ASND is the smaller challenger ($17.03B), actually pricier on forward earnings (25.89x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.

ASND vs NVO: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricASNDNVOWhat it tells you
Market cap$17.03B$178.19BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E25.8911.94Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Trailing P/E19.8310.21Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price.
Price vs 52-week range75% of range18% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book10.535.45How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Reading it: NVO is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

Before you buy: how ASND and NVO affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ASND and NVO share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ASND and NVO exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does Ascendis Pharma (ASND) do?

Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. The business is built on TransCon, a prodrug technology that attaches a known parent drug to a carrier through a linker that releases the active molecule slowly and predictably, which lets Ascendis convert daily injections into weekly or monthly dosing. Three products are approved and marketed: SKYTROFA (lonapegsomatropin) for pediatric growth hormone deficiency, YORVIPATH (palopegteriparatide) for adult hypoparathyroidism, and YUVIWEL (navepegritide, developed as TransCon CNP), which received accelerated FDA approval with orphan exclusivity in May 2026 for pediatric achondroplasia. On October 16, 2026 the European Medicines Agency's CHMP issued a positive opinion recommending TransCon CNP for children with achondroplasia, the step that normally precedes a European Commission decision. Trailing twelve month revenue is roughly EUR 1.05 billion, with gross margin near 91 percent.

Full ASND guide

What does Novo Nordisk (NVO) do?

Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. Its franchise centers on GLP-1 receptor agonists, most notably semaglutide, sold as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management. Novo Nordisk also holds a long-standing leadership position in insulin and broader diabetes therapies, and maintains smaller franchises in rare blood and endocrine disorders. The company is headquartered in Bagsvaerd, Denmark, and is controlled by the Novo Nordisk Foundation through a dual-share structure. US investors typically access it through the NVO American Depositary Receipt listed on the New York Stock Exchange, which represents the Danish B shares. The explosive demand for GLP-1 drugs for both diabetes and weight loss has made Novo Nordisk one of Europe's most valuable companies, while also straining its manufacturing capacity for injectable medicines.

Full NVO guide

ASND vs NVO: how do they differ?

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

  • ASND drivers: YORVIPATH is carrying the model; YUVIWEL opens a second large launch.
  • NVO drivers: GLP-1 obesity and diabetes demand; Pipeline and next-generation candidates.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. For NVO, novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year.

ASND or NVO: which should you pick?

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ASND if you believe its drivers more; NVO if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ASND and NVO guides.

ASND vs NVO: the full fundamentals

ASND. The trailing earnings multiple is the number most likely to mislead here, because trailing net income is driven largely by the roughly EUR 679 million deferred tax asset recognized in the first quarter of 2026, not by operations. Price to sales near 14x and forward price to earnings near 21x are the cleaner framing, and both price in continued rapid growth; consensus calls for third-quarter revenue of about EUR 367 million. The mean analyst target of about $307 across 21 analysts sits well above the $226 share price.

NVO. Novo Nordisk once commanded a premium pharma multiple on the strength of GLP-1 growth; at about 9x trailing and 11x forward earnings in October 2026 it now trades at a discount that reflects slowing sales and share loss to Eli Lilly. Trailing net income is lifted by an unusually large Q1 2026, which is one reason forward earnings estimates sit below trailing ones. Figures are reported in Danish kroner (market cap and the ADR dividend in dollars) and should be verified against the latest filings; Q3 2026 results are due November 4.

Headline figures (approximate, October 2026): ASND shows market cap ~$14.9 billion at ~$226 per share (Oct 16, 2026), revenue (ttm) ~EUR 1.05 billion; Q2 2026 ~EUR 340 million, up ~115%, q2 2026 eps 0.90 vs ~0.77 consensus, profitability Gross margin ~91%; TTM net income ~EUR 742 million, inflated by a ~EUR 679 million one-time tax asset; NVO shows revenue (ttm) ~DKK 329 billion (+2% YoY in Q2 2026), revenue (2026 consensus) ~DKK 301 billion, operating margin (ttm) ~43%, net margin (ttm) ~35%.

The bottom line: ASND vs NVO

ASND and NVO are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ASND and NVO exposure against your real portfolio. It is not an investment adviser.

Wondering how ASND or NVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Ascendis Pharma

Ask Walnut's AI anything about ASND and see how it fits what you own.

FAQ

What is the difference between ASND and NVO?

+

Ascendis Pharma A/S trades on Nasdaq under ASND as American Depositary Shares, each representing one ordinary share of a company headquartered in Hellerup, Denmark. Novo Nordisk (NVO) is a Danish pharmaceutical company and a global leader in diabetes and obesity care. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is ASND or NVO the better stock?

+

Neither is universally better. NVO is the larger incumbent; ASND is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, ASND or NVO?

+

On forward P/E (as of November 2026), ASND trades at 25.89x and NVO at 11.94x, so NVO is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both ASND and NVO?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of ASND vs NVO?

+

ASND: Revenue concentration is the dominant risk: one product supplies the large majority of sales, so a safety signal, a manufacturing interruption, or faster than expected competition in hypoparathyroidism would hit the whole model. AstraZeneca's eneboparatide and other parathyroid hormone programs target the same indication, while BioMarin's Voxzogo is entrenched in achondroplasia and a long-acting successor is in development, and oral FGFR3 approaches could reframe the category entirely; in October 2026 the FDA granted priority review to BridgeBio's achondroplasia filing. YUVIWEL was cleared under accelerated approval, which carries confirmatory evidence obligations that can constrain or withdraw a label. Taking back TransCon Semaglutide moves the cost and risk of an obesity program, a field crowded with the largest drugmakers, onto Ascendis alone. UBS cut its price target to $269 from $307 in October 2026. Ascendis is a foreign private issuer that reports in euros and files Form 20-F, so currency translation and a lighter interim disclosure cadence than a domestic filer both apply. On the legal side, Ascendis is an appellant in patent litigation against BioMarin at the Federal Circuit (No. 26-1026), and plaintiffs' firms publicized securities class action investigation notices in 2023 following the FDA deficiency letter on TransCon PTH, though those solicitations are not the same as a filed complaint and no active securities-fraud class action was identified as of August 2026. NVO: Novo Nordisk is heavily concentrated in a single drug class, so any clinical setback, safety signal, or faster-than-expected competition from Eli Lilly's tirzepatide (Mounjaro, Zepbound) and newer entrants directly threatens the core franchise; 2026 has shown that risk playing out, with revenue growth near 2% in Q2 and consensus calling for a small decline for the year. Oral competitors, including Lilly's Foundayo (backed by an EMA panel in October 2026) and Viking's Phase 3 pill, raise the pressure further. Manufacturing capacity has been a persistent constraint, limiting how much demand it can serve. US drug pricing, payer coverage decisions, and potential price negotiation add reimbursement risk to its largest market. As an ADR, NVO carries Danish krone currency exposure and is influenced by European regulation. Patent expiries and the eventual arrival of biosimilar or generic competition loom over the long-term semaglutide economics. Debt has also risen with the capacity build (about DKK 140 billion against about DKK 45 billion of cash at mid-2026).

Related comparisons

Browse all stock comparisons.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ASND or NVO; figures are approximate and dated (as of November 2026). Verify current data before investing.